Raising the bar in liver cancer therapy

ASCO 2018 - Monday 4th June: BMS tries different tack as Mer...

Merck & Co has dominated proceedings at the American Society of Clinical Oncology (ASCO), with a steady flow of data from its Keytruda checkpoint inhibitor drug at the conference in Chi

Puma gains as Roche breast cancer combo disappoints

ASCO serves up shock as Roche's data disappoints

ASCO to shine light on CAR-T developments

Kite, Juno, and BlueBird will give updates on T-cell therapies.

ASCO 2017: Breast cancer next target for Keytruda

Immunotherapy combinations will be the focus - but attention is shifting towards these agents proving their overall survival benefits.

Tunnah’s musings: Lessons for pharma from digital ASCO 2016

Pharma needs to remedy its approach to digital conference engagement.